Shiseido Trial Update, Topical Reverses Baldness after Decades: Weekly Thoughts 7/1/16
Hey everybody and welcome to another installment of Weekly Thoughts.
This week we get an encouraging update about the logistics of Shiseido’s trial and more information about the RiverTown Therapeutics compound.
Shiseido Closer to Trial
News was finally released this week about the upcoming trial that Shiseido will be conducting in Japan for Replicel’s RCH-01 therapy. Shiseido acquired an exclusive license in 2013 to bring Replicel’s hair regeneration therapy to market for Asian countries. Since then, it was known that Shiseido would be implementing it’s own clinical trials of RCH-01 in Japan which would bring RCH-01 to market much sooner than the US clinical trial timelime. Many had thought that Shiseido’s trial would commence in 1st half 2016, but that was not the case. It appears that Shisiedo is finally ready to commence it’s trial in Japan which would be the only trial necessary to bring the therapy to market, as long as the therapy showed efficacy/safety initially and maintained safety after the duration of the trial.
The details that we know so far for the trial include:
- 60 men and women
- Tokyo Medical University Hospital & Toho University Ohashi Medical Center for the sites
- Study will continue for 3 years to observe efficacy and especially safety
- No official start date yet, but appears to be within 3rd quarter 2016
*This does not mean the trial would take 3 years to complete before the therapy could be out on market. I am not certain, but I believe the timeline of the actual trial would be about 1.5 years and then the therapy can be approved and released, the remaining time is to keep watch and make sure there are no adverse effects that develop over time.
RiverTown’s ‘a flowing
Rivertown Therapeutics was part of the Mid Atlantic Bio Angels 1st Pitch Life Science Competition this month and tied for the “Best in Show” honors along with 6Degrees company. It’s definitely an encouraging sign for this intriguing newcomer to the hair growth tech scene. The lead therapy candidate being shown off by RiverTown Therapeutics is named RT-1640 and is reportedly a combination of three agents that have strong safety profiles and have been used in humans for a long time. The effect of these agents combined is claimed to reactivate hair follicles and even rejuvenate the melanocyte stem cells (cells responsible for giving hair it’s color). What was even more interesting was a quote that David Weinstein, MD, founder of RT, provided for the write up about his success at the event:
“Hair regeneration and maintenance are complex processes that involve multiple pathways. The components in RT1640 restart the hair growth process and support the nascent and mature hair. The net result is the growth of new hair, even after decades of baldness,”
Decades?…….Decades as in groups of 10 years? Those kind of decades? We’ve never heard of a topical that could revive hair follicles after they had been severely shrunken for many years. That’s pretty impressive. According to the myBio 2016 event RiverTown’s RT1640 is currently in Phase II of clinical trials. The company seems to be doing very well in terms of attracting investors and certainly that trend looks to continue.
As they say, “things are looking up.” Stay grateful everyone and be well.